Fig. 3: KMT2A::MLLT3+ CSF1R+ LMPPs have AML-propagating properties.

A Experimental layout of secondary transplants. 200.000 total bone marrow cells from CSF1R- primary recipients (n = 2) and CSF1R+ primary recipients (n = 3) were intravenously injected into NSG mice (6 recipients each). CSF1R- donor cells failed to engraft secondary recipients, while all CSF1R+ recipients showed similar chimerism. B Survival curve of NSG secondary recipients that received total bone marrow cells from CSF1R- and CSF1R+ primary recipients. C Percentages of donor CD11b+ Gr1+ and CD11b+ Gr1+ cKIT+ cells in the bone marrow, peripheral blood, and spleens of CSF1R+ secondary recipients. Percentages of CD11b+ Gr1+ cells are shown within CD45.2+ cells; percentages of cKIT+ cells are shown within CD11b+ Gr1+ cells. D Representative picture of May-Grünwald Giemsa staining of peripheral blood smear (PB, left) and pale bones (BM, right) from secondary CSF1R+ NSG recipients. Black arrow indicates the presence of myeloblast cells; scale bar = 0.5 µm. E Representative picture of spleen enlargement and leukaemia infiltration (black arrow) in secondary CSF1R+ NSG recipients. F Liver histological sections (Haematoxylin-Eosin staining) of CSF1R- secondary recipients, and leukaemic liver from secondary CSF1R+ NSG recipients (left panel scale bar = 200 µm, right panel scale bar = 20 µm). White box area shown at higher magnification on the right. G Representative picture of CNS histological sections of leukaemia infiltration in CSF1R+ secondary recipients (lower panel) compared to CSF1R- secondary recipients (upper panel); scale bar 500 µm. Survival differences were analysed with the Gehan-Breslow-Wilcoxon test. CNS (central nervous system).